Parathyroid Hormone-Related Protein for the Treatment of Postmenopausal Osteoporosis: Defining the Maximal Tolerable Dose

Context: PTH is the only approved skeletal anabolic agent for the treatment of human osteoporosis. Unlike PTH, which is a mixed anabolic and catabolic agent, PTHrP displays features suggesting that it may be a pure anabolic agent when intermittently administered. The full dose range of PTHrP is unkn...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Horwitz, Mara J., Tedesco, Mary Beth, Garcia-Ocaña, Adolfo, Sereika, Susan M., Prebehala, Linda, Bisello, Alessandro, Hollis, Bruce W., Gundberg, Caren M., Stewart, Andrew F.
Format: Artigo
Jezik:Inglês
Izdano: The Endocrine Society 2010
Teme:
Original Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2841539/
https://ncbi.nlm.nih.gov/pubmed/20061412
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2009-0233
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items